Abstract
In this interesting experimental study, the authors compared the effects of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin with telmisartan in the progression of chronic kidney disease (CKD) induced in non-diabetic rats by 5/6 nephrectomy (Nx). Four groups of Wistar rats were studied: sham-operated plus placebo; 5/6Nx plus placebo; 5/6 Nx plus linagliptin; and 5/6 Nx plus telmisartan. The results showed that both drugs reduced albumin excretion when compared with the group 5/6 Nx plus placebo. Linagliptin did not lower blood pressure, but it attenuated renal interstitial fibrosis by restoring collagen type I protein expression and also decreased glomerular hypertrophy. In contrast, telmisartan lowered blood pressure, and showed anti-inflammatory and immunomodulatory effects by restoring CD68 renal protein expression and lowering plasma levels of macrophage colony-stimulating factor 1. Another interesting finding was that only telmisartan reduced oxidative stress in this model of CKD. A second study with 5/6 nephrectomy wild-type and genetically deficient DPP-4 rats treated with placebo or linaglipitin confirmed the effective antiproteinuric effect of linaglipitin therapy in both types of rats. It would be interesting to measure inulin clearance, since both drugs did not modify cystatin C levels, and also to look at another group -- Nx plus linagliptin and telmisartan -- in order to verify if this association may increase the beneficial effect on prevention of CKD progression. This beneficial effect of linaglipitin on CKD progression would be interesting to evaluate in clinical studies with nondiabetic patients.